Dr. James H. Thrall discusses our upcoming conference on Imaging Biomarkers in Clinical Trials.
Imaging Biomarkers in Clinical Trials: Focus on Oncology
Friday, April 26 and Saturday, April 27, 2013
Imaging biomarkers serve as important endpoints for clinical trials in the approval process for therapeutic drugs. Various criteria have been developed for objective interpretation of imaging studies. Additionally, there are emerging imaging techniques that have the potential for applications as surrogate endpoints for clinical trials. In this program, we will review the current practice of imaging biomarkers in clinical trials in oncology. Additionally, we will highlight advanced imaging techniques that have potential as surrogate biomarkers.
